Spin-offs

DyNAbind GmbH

DyNAbind is a biotechnology spin-off company offering drug discovery partnerships that leverage its proprietary platform of DNA-Encoded Library (DEL) technologies for early drug discovery and hit optimization. The DEL approach allows the simultaneous screening of up to billions of potential drug molecules against a target protein of interest. Originally developed in the lab of Professor Yixin Zhang at the B CUBE, these technologies were spun out and commercialized as the B CUBE’s first spinout by CEO Dr. Michael Thompson and COO Dr. Norbert Höfgen in 2017. The project was initially funded through an EXIST Forschungstransfer grant, with later growth and expansion coming from a seed financing round with multiple European venture capital firms. 

Link to: www.dynabind.com

denovoMATRIX GmbH

denovoMATRIX is an extracellular matrix engineering company, spinned off the group of Prof. Yixin Zhang at B CUBE in 2018, that enables the acceleration of cell based therapies and development in stem cell research. The company leverages chemical synthesis, stem cell biology and design thinking to build a platform of biomaterials which address major life science challenges. By providing both cell based therapy companies and academic researchers with solutions, denovoMATRIX is at the forefront of innovation in biomaterials.

Link to: www.denovomatrix.com